Weight-loss Pill Approval Set to Accelerate Food Industry Product Overhauls
Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become… Reuters Health Information
Healthcare, Vol. 14, Pages 60: 12-Month Weight Loss and Adherence Predictors in a Real-World UK Tirzepatide-Supported Digital Obesity Service: A Retrospective Cohort Analysis
Healthcare, Vol. 14, Pages 60: 12-Month Weight Loss and Adherence Predictors in a Real-World UK Tirzepatide-Supported Digital Obesity Service: A Retrospective Cohort Analysis Healthcare doi: 10.3390/healthcare14010060 Authors: Louis Talay Jason Hom Tamara Scott Neera Ahuja Background: Obesity management is evolving with the integration of dual GIP/GLP-1 receptor agonists (Tirzepatide) into comprehensive Digital Weight-Loss Services (DWLSs). […]
Marriage and Sex in the Age of Ozempic: An Update
This week, The Daily is revisiting some of our favorite episodes of the year and checking in on what has happened in the time since. In the past few years, GLP-1 weight-loss drugs like Ozempic and Zepbound have been radically reshaping the people’s lives, changing appetites and health. But the drugs also have the power […]
4 anti-aging approaches revealed in 2025 that may help Americans live longer
On average, Americans want to live to be 91 years old, according to a recent Pew Research survey — a goal that has driven a focus on longevity-boosting practices. Over 60% of U.S. adults use supplements and most prioritize long-term health and wellness behaviors as part of an anti-aging approach, research has shown. In 2025, […]
GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market – Global Forecast to 2033: Growing Shift of Weekly Injectables Toward Orals and Multi-Agonists – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, Tirzepatide), Type (Patented, Biosimilars), Format (Single Dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) – Global Forecast to 2033” report has been added to ResearchAndMarkets.com’s offering. The GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 […]
The best photos of 2025
We are very fortunate at AP to be able to view thousands of fantastic images each year. It’s not easy to choose a favourite but here are a few that that stuck with us in 2025 along with images chosen by picture editors – photographs shaped by conflict, crisis and fleeting moments of humanity. The […]
JCM, Vol. 15, Pages 181: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Stable Kidney Transplantation: Clinical Outcomes from a Cohort of Patients with Post-Transplant Diabetes Mellitus
JCM, Vol. 15, Pages 181: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Stable Kidney Transplantation: Clinical Outcomes from a Cohort of Patients with Post-Transplant Diabetes Mellitus Journal of Clinical Medicine doi: 10.3390/jcm15010181 Authors: Ricardo E. T. Navarrete Joana Freitas Isabel Fonseca Ana Cunha Joao Roberto Sa La Salete Martins Background: Despite the lack of formal […]
Narendra Solanki sees select opportunities in metals, GLP-1 and solar plays
Amid global uncertainty, market expert Narendra Solanki advises theme-based investing. He highlights opportunities in specific metals like steel and copper, niche pharma plays focusing on GLP-1 drug delivery mechanisms, and renewable-linked manufacturing, particularly solar pump companies benefiting from government schemes. This selective approach targets companies with cost advantages and policy support for growth.
HIMS Might be Undervalued by ~ 20%?
I valued Hims 6 months ago at ~$34/share. Back then my main thesis was that telehealth was a low-margin business, subscriber growth was fueled by gobs of marketing spend, that their fastest growing vertical (GLP-1 meds) faced regulatory hurdles, and the business competed in a fragmented and highly competitive D2C space. I decided to take […]
Weight-loss therapy set to push pharma growth
India’s obesity drug market is booming, poised for significant growth driven by rising lifestyle diseases and upcoming affordable generics. Experts anticipate wider access to GLP-1 medicines, accelerating innovation through AI, and a shift towards complex generics. This transformative phase promises improved patient outcomes and positions India as a key player in global healthcare advancements.